PJ Vogt

I wanted to know if she had a perspective on a class of drugs that are adjacent to, but in my view, fairly different from GLP-1s, internet peptides, the wilder west of molecules many people are now using, drugs we've covered elsewhere on the show.

And is that a bad shift?

Is that a neutral shift?

I can't tell if what you're describing is that interventions that we just would have understood as cosmetic before are becoming much more socially acceptable or if it's more complicated, which is that like interventions like we thought of as cosmetic were now in our own minds labeling as medical.

Yeah.

But it's like you feel uneasy, but you feel uncertain about your uneasiness.

I think that's an intellectually honest position.

Thank you for talking about this.

Dr. Rachel Bedard, she's a doctor and writer.

We'll have a link to her story about the rise of Ozempic in the show notes.

Also, I have to say, there was one more part of this conversation, which it was the part I found myself talking the most about with friends the week afterwards, but it was on a slightly adjacent topic.

So we got more into this idea of cosmedicine, like the place where cosmetic interventions and medical interventions kind of meld together.

and about how there are middle-aged people who are thinking about interventions like taking testosterone or estrogen, or going to the dermatologist for lasers to try to look more the way they think Anne Hathaway looks, or men going to Turkey to get a new hairline.

I don't know how we're supposed to think about this era where looking older seems to be becoming more optional, where many people on the internet seem forever 35.

And talking to Dr. Bedard, who is also working this stuff out, it really helped me.

These ideas have already been swirling around my brain.

It settled them a little bit.

If you want to hear that conversation, we're going to publish it as an extra small feature on incognito mode.

You can sign up for that at searchengine.show.

If you're already signed up, it is in your feed now.